Lumos Signs Major Development and IP Agreements with Hologic
6 May 2024
Lumos Diagnostics has announced that it has successfully completed the first phase of its Development Agreement to develop a new fetal fibronectin (fFN) test for leading women’s health company, Hologic, Inc.
The focus of the Development Agreement is a next generation version of Hologic’s on- market fFN diagnostic product for pre-term birth. A key focus of the program is to develop the test for use on Lumos’ proprietary reader platform and provide improved connectivity options.
Lumos Diagnostics CEO and Managing Director, Doug Ward, said:
"We are very pleased to have completed this critical first phase of this Development Agreement with Hologic. Achieving milestone approval from Hologic is excellent validation of the project work completed by the Lumos team, whilst providing additional strength to the company balance sheet through further project funding and a positive outlook on the likelihood of Lumos delivering on subsequent phases."
Click here to read today’s ASX release.
The focus of the Development Agreement is a next generation version of Hologic’s on- market fFN diagnostic product for pre-term birth. A key focus of the program is to develop the test for use on Lumos’ proprietary reader platform and provide improved connectivity options.
Lumos Diagnostics CEO and Managing Director, Doug Ward, said:
"We are very pleased to have completed this critical first phase of this Development Agreement with Hologic. Achieving milestone approval from Hologic is excellent validation of the project work completed by the Lumos team, whilst providing additional strength to the company balance sheet through further project funding and a positive outlook on the likelihood of Lumos delivering on subsequent phases."
Click here to read today’s ASX release.
